SignalPoint Asset Management LLC raised its stake in Johnson & Johnson (NYSE:JNJ) by 9.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,339 shares of the company’s stock after purchasing an additional 930 shares during the quarter. SignalPoint Asset Management LLC’s holdings in Johnson & Johnson were worth $1,454,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Sector Gamma AS grew its holdings in Johnson & Johnson by 0.3% during the 1st quarter. Sector Gamma AS now owns 117,532 shares of the company’s stock valued at $15,412,000 after purchasing an additional 303 shares in the last quarter. Tradewinds Capital Management LLC boosted its position in Johnson & Johnson by 1.3% in the 1st quarter. Tradewinds Capital Management LLC now owns 7,602 shares of the company’s stock valued at $997,000 after buying an additional 101 shares during the last quarter. Pennsylvania Trust Co boosted its position in Johnson & Johnson by 1.3% in the 1st quarter. Pennsylvania Trust Co now owns 409,496 shares of the company’s stock valued at $53,698,000 after buying an additional 5,413 shares during the last quarter. Private Asset Management Inc. grew its stake in shares of Johnson & Johnson by 0.5% during the second quarter. Private Asset Management Inc. now owns 93,956 shares of the company’s stock valued at $13,213,000 after acquiring an additional 425 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board increased its position in shares of Johnson & Johnson by 5.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 555,611 shares of the company’s stock worth $72,857,000 after acquiring an additional 27,525 shares during the last quarter. Institutional investors own 68.44% of the company’s stock.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. The stock has a market capitalization of $383.76 billion, a price-to-earnings ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. Johnson & Johnson has a twelve month low of $109.16 and a twelve month high of $157.00. The company has a current ratio of 1.25, a quick ratio of 1.05 and a debt-to-equity ratio of 0.40. The business’s 50 day simple moving average is $144.04 and its 200-day simple moving average is $144.14.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The firm had revenue of $18.34 billion for the quarter, compared to analyst estimates of $17.73 billion. Johnson & Johnson had a return on equity of 35.21% and a net margin of 22.69%. The firm’s revenue for the quarter was down 10.8% on a year-over-year basis. During the same period last year, the company earned $2.58 earnings per share. Sell-side analysts predict that Johnson & Johnson will post 7.85 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be given a $1.01 dividend. The ex-dividend date of this dividend is Monday, August 24th. This represents a $4.04 annualized dividend and a yield of 2.77%. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
A number of equities research analysts have weighed in on the company. ValuEngine lowered Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, July 15th. Bank of America reissued a “buy” rating on shares of Johnson & Johnson in a research report on Monday, July 20th. Barclays upped their price target on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. UBS Group lowered shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $163.00 to $160.00 in a report on Tuesday, April 28th. Finally, Independent Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and upped their target price for the company from $161.00 to $164.00 in a research note on Monday, July 20th. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $163.38.
In other Johnson & Johnson news, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.27% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: What is the yield curve?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.